medigraphic.com
ISSN 1729-519X (Print)

2019, Number 1

<< Back Next >>

Revista Habanera de Ciencias Médicas 2019; 18 (1)

Relapse of disease among lupus Hispanic patients with chronic kidney disease treated with hemodialysis. Case Presentations

Herrera-Añazco P, Velázquez-Castillo P, Arellán-Bravo L

Language: Spanish
References: 26
Page: 88-96
PDF size: 555.15 Kb.


ABSTRACT

Introduction: Patients with systemic lupus erythematosus (SLE) have a decrease in the activity of the disease when it evolves to chronic kidney disease (CKD). Relapses of SLE have been published in this stage in different ethnic groups, but not in Hispanic patients who are traditionally associated with a worse prognosis.
Objective: To describe the cases of patients with CKD undergoing hemodialysis with a diagnosis of disease relapse.
Case presentations: We present 4 cases (2 men and 2 women) with an average age of 28 years. They had an average SLEDAI score without renal criteria of 20.25, and presented exacerbations of different characteristics. All these patients received immunosuppressive treatment and 2 of them died.
Conclusions: Our health system should establish adequate follow-up measures for patients with frequent evaluations of the activity and the disease so that it allows to make an early diagnosis and treatment. Our health system should implement new measures for the followup of patients with SLE receiving hemodialysis for the early diagnosis and treatment of relapses due to SLE.


REFERENCES

  1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) [Internet]. 2017 Nov [cited 23/08/2019]; 56(11):1945-1961. Available from: https://academic.oup.com/rheumatology/article -lookup/doi/10.1093/rheumatology/kex260

  2. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999- 2012. Ann Rheum Dis [Internet]. 2016 [cited 23/08/2018] Jan; 75(1):136-41. Available from: https://ard.bmj.com/content/75/1/136.long

  3. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. [Internet]. 2012 [cited 23/08/2018]; 27(8):3248–54. Available from: https://academic.oup.com/ndt/articlelookup/ doi/10.1093/ndt/gfs073

  4. Maroz N, Segal MS. Lupus nephritis and endstage kidney disease. Am J Med Sci[internet] 2013 [cited 23/08/2018]; 346(4):319–23. Available from: https://www.amjmedsci.org/article/S0002- 9629(15)30521-8/fulltext

  5. Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol [Internet]. 2013 Jan-Feb [cited 23/08/2018]; 31(1):31-9. Disponible en: http://www.clinexprheumatol.org/abstract.asp? a=5501

  6. Barrera-Vargas A, Quintanar-Martínez M, Merayo-Chalico J, Alcocer-Varela J, Gómez- Martín D. Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study. Rheumatology (Oxford). [Internet]. 2016 Mar [cited 23/08/2018]; 55(3):429-35. Available from https://academic.oup.com/rheumatology/article lookup/doi/10.1093/rheumatology/kev349

  7. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis [Internet]. 2000 [cited 23/08/2018]; 35 (4):611– 16. Available from: https://www.ajkd.org/article/S0272- 6386(00h)70006-0/fulltext

  8. Mejía-Vilet JM, Córdova-Sánchez BM, Arreola- Guerra JM, Morales-Buenrostro LE, Uribe-Uribe N. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. [Internet]. 2016 Mar [cited 23/08/2018]; 25(3):315-24. Available from: https://journals.sagepub.com/doi/abs/10.1177/ 0961203315606985?rfr_dat=cr_pub%3Dpubme d&url_ver=Z39.88- 2003&rfr_id=ori%3Arid%3Acrossref.org&journal Code=lupa

  9. Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephron [Internet] 2014 Feb [cited 23/08/2018]; 9(2):279-84. Available from: https://cjasn.asnjournals.org/content/9/2/279.l ong

  10. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr [Internet]. 2012 [cited 23/08/2018]; 22(1):149-56. Disponible en: https://www.jrnjournal.org/article/S1051- 2276(11)00210-X/fulltext

  11. Althaf MM, Abdelsalam MS, Alfurayh OI. Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy– case series. Lupus. [Internet]. 2014 Aug [cited 23/08/2018]; 23(9):945-8. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/ 0961203314530487?rfr_dat=cr_pub%3Dpubme d&url_ver=Z39.88- 2003&rfr_id=ori%3Arid%3Acrossref.org&journal Code=lupa

  12. Mattos P, Mittermayer BS. Disease activity in systemic lupus erythematosus patients with endstage renal disease: systematic review of the literatura. Clin Rheumatol [Internet]. 2012 Jun [citado 23/08/2018]; 31(6):897-905. Disponible en: https://link.springer.com/article/10.1007%2Fs10 067-012-1957-9

  13. Contreras G, Lenz O, Pardo V, Borja E, Cely C. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int [Internet]. 2006 [cited 23/08/2018]; 69(10):1846-51. Available from: https://www.kidneyinternational. org/article/S0085-2538(15)51340- 9/fulltext

  14. Pahl MV, Gollapudi S, Sepassi L Effect of endstage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant [Internet]. 2010 [cited 23/08/2018]; 25(1):205-12. Available from: https://academic.oup.com/ndt/articlelookup/ doi/10.1093/ndt/gfp397

  15. Lim WH, Kireta S, Russ GR, Coates PT. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int [internet] 2007 [citado 23/08/2018]; 71(11):1122-31. Disponible en: https://www.kidneyinternational. org/article/S0085-2538(15)52275- 8/fulltext

  16. Cucchiari D, Graziani G1, Ponticelli C. The dialysis scenario in patients with systemic lupus erythematosus. Neph Dial Transp. [Internet]. 2014 Aug [cited 23/08/2018];29(8):1507-1513. Available from: https://academic.oup.com/ndt/article/29/8/150 7/1938224

  17. Ribeiro FM, Leite MA, Velarde GC, Fabris CL, Santos RC. Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol. [Internet]. 2005 [cited 23/08/2018]; 25(6):596–603. Available from: https://www.karger.com/Article/Abstract/89708

  18. Kang SH, Chung BH, Choi SR, Lee JY, Park HS, In-O S. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med [Internet]. 2011 [cited 23/08/2018]; 26(1):60-67. Available from: http://kjim.org/journal/view.php?doi=10.3904/k jim.2011.26.1.60

  19. Nossent HC, Swaak TJ, Berden JH: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on LES. Am J Med [Internet].1990 [citado 23/08/2018]; 89(2): 169–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/238266 5

  20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum [internet] 1992 [cited 23/08/2018]; 35(6):630–640. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002 /art.1780350606?sid=nlm%3Apubmed

  21. Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Mengozzi G, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol [Internet]. 2005 [cited 23/08/2018]; 18(3): 282–288. Disponible en: https://www.researchgate.net/publication/7731 673_Procalcitonin_as_a_marker_of_microinflammation_ in_hemodialysis

  22. Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ, et al. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev [Internet]. 2012 [citado 23/08/2018]; 12(2): 157– 163. Available from: https://www.sciencedirect.com/science/article/ abs/pii/S1568997212000791?via%3Dihub

  23. Broder A, Khattri S, Patel R, Putterman C. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol [Internet]. 2011 [cited 23/08/2018]; 38(11): 2382–2389. Available from: http://www.jrheum.org/content/38/11/2382.lo ng

  24. Lewis MJ, Jawad A. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford). [Internet]. 2017 Apr [internet]; 56(suppl_1):i67- i77. Disponible en: https://academic.oup.com/rheumatology/article /56/suppl_1/i67/2629213

  25. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. [Internet]. 2018 [citado 23/08/2018]; 14(18):1043-1053. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/ 1744666X.2018.1538789?journalCode=ierm20

  26. Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore). [Internet]. 2004 Jan [citado 23/08/2018]; 83(1):1-17. Disponible en: https://insights.ovid.com/pubmed?pmid=14747764




2020     |     www.medigraphic.com